True Wealth Design LLC Boosts Holdings in Illumina, Inc. (NASDAQ:ILMN)

True Wealth Design LLC lifted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 25,350.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 509 shares of the life sciences company’s stock after purchasing an additional 507 shares during the period. True Wealth Design LLC’s holdings in Illumina were worth $66,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Bank of New York Mellon Corp boosted its position in Illumina by 7.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 3,039,538 shares of the life sciences company’s stock valued at $317,267,000 after buying an additional 204,043 shares during the last quarter. Primecap Management Co. CA boosted its holdings in Illumina by 3.6% in the third quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company’s stock valued at $328,158,000 after purchasing an additional 87,599 shares during the last quarter. Millennium Management LLC grew its stake in Illumina by 305.0% during the 2nd quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company’s stock valued at $155,067,000 after purchasing an additional 1,118,747 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Illumina by 4.5% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,260,137 shares of the life sciences company’s stock worth $164,334,000 after purchasing an additional 54,319 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its position in shares of Illumina by 148.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company’s stock valued at $137,735,000 after purchasing an additional 631,294 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Stock Down 0.1 %

NASDAQ:ILMN opened at $144.15 on Friday. Illumina, Inc. has a 1-year low of $99.23 and a 1-year high of $156.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The business’s fifty day moving average price is $141.88 and its 200 day moving average price is $125.95.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. During the same period in the prior year, the firm earned $0.33 earnings per share. The firm’s revenue was down 3.5% compared to the same quarter last year. As a group, equities research analysts expect that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Robert W. Baird raised their price objective on shares of Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Barclays lifted their price target on Illumina from $135.00 to $145.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. Daiwa America raised Illumina to a “strong-buy” rating in a report on Friday, August 16th. UBS Group lifted their target price on Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, Daiwa Capital Markets upgraded Illumina from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $120.00 to $154.00 in a research note on Friday, August 16th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Illumina presently has a consensus rating of “Moderate Buy” and a consensus target price of $164.00.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.